Summit Therapeutics (SMMT) has agreed to sell ridinilazole, an investigational phase 3 precision antibiotic, to Toronto-based Biossil, the company said Tuesday.
Under the agreement, Summit will receive $500,000 upfront and up to $104.5 million in regulatory and commercial milestones, along with tiered royalties on net sales.
Summit said Biossil plans to continue clinical development of the asset while it focuses on its oncology strategy and development of ivonescimab, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.